TABLE 3.
Distribution of pulsotypes by locale and source among 133 isolates of E. coli ST1193
| Pulsotypea | No. of isolates |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total (n = 133) | United States |
Australian clinicalc |
|||||||
| Fecalb MVAMC, 2014–2018 |
Clinicalb,c |
||||||||
| Human (n = 28) | Dog (n = 1) | MVAMC, 2010–2018 (n = 68) | 24 VAMCs, 2011 (n = 4) | Olmsted County, MN, 2011 (n = 2) | UMMC, 2013 (n = 4) | Human, 2008 (n = 24) | Dog, 2008 (n = 2) | ||
| 1297 | 56 | 14 | 1 | 26 | 2 | 2 | 3 | 8 | 0 |
| 2123 | 29 | 6 | 0 | 23 | 0 | 0 | 0 | 0 | 0 |
| 1298 | 18 | 1 | 0 | 2 | 0 | 0 | 0 | 14 | 1 |
| 2361 | 10 | 3 | 0 | 5 | 0 | 0 | 1 | 0 | 1 |
| 2359 | 4 | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| 2364 | 4 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| 2362 | 3 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| 2365 | 3 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
Of 13 total ST1193 pulsotypes, 8 (shown in the table) accounted for ≥3 isolates each (127 total isolates; 95% of 133). The remaining 5 ST1193 pulsotypes accounted for either 2 isolates (pulsotype 2366; 2 MVAMC clinical isolates) or 1 isolate (3 MVAMC clinical isolates, 1 Australian human isolate) each.
Among U.S. isolates, all prevalence comparisons between fecal and clinical isolates for individual pulsotypes, P > 0.50 (Fisher’s exact test).
Among clinical isolates, the U.S. and Australian isolates differed significantly for the prevalence of pulsotypes 2123 (23/68 [28%] [United States] versus 0/26 [0%] [Australian]; P < 0.001) and 1298 (2/68 [3.0%] [United States] versus 15/26 [58%] [Australian]; P < 0.001). For all other pulsotypes, P was >0.05.